Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Small

Internal Medicine Hoffman Estates, IL Medical Doctor

NPI 1689690463 CMS profile 923590

1585 Barrington Rd Ste 204, Hoffman Estates, IL 60169

Open in the dashboard

General payments

$5,279

251 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Small of Hoffman Estates, IL is reported in the CMS Open Payments database as having received $5,279 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $465 21
2024 General $576 24
2023 General $667 31
2022 General $767 37
2021 General $1,038 52
2020 General $967 43
2019 General $799 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Small
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Small were reported at $465. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Small Internal Medicine median Middle half National median
2019 $799 $159 $48–$570 $163
2020 $967 $119 $33–$402 $114
2021 $1,038 $135 $37–$521 $132
2022 $767 $141 $42–$496 $149
2023 $667 $149 $45–$519 $160
2024 $576 $154 $47–$537 $164
2025 $465 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,306 54 payments
  2. Janssen Pharmaceuticals, Inc $830 46 payments
  3. Amgen Inc. $568 28 payments
  4. GlaxoSmithKline, LLC. $540 27 payments
  5. Pfizer Inc. $418 17 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $395 16 payments
  7. Amarin Pharma Inc. $323 20 payments
  8. Lilly USA, LLC $151 6 payments
  9. Exact Sciences Corporation $111 4 payments
  10. Merck Sharp & Dohme Corporation $105 5 payments
  11. Other $532 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,244 248 payments
  2. Education $35 3 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $918 33 payments
  2. XARELTO $748 42 payments
  3. TRELEGY ELLIPTA $479 23 payments
  4. SYMBICORT $371 10 payments
  5. Vascepa $323 20 payments
  6. Otezla $267 13 payments
  7. JARDIANCE $266 11 payments
  8. Repatha $262 14 payments
  9. ELIQUIS $238 9 payments
  10. EVENITY $222 10 payments
  11. Other $3,010 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 92 drugs

Part D claims

5,224

Median for Internal Medicine: 777

Drug cost

$282,079

Median for Internal Medicine: $73,373

Branded share of claims

12.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 40 $49,437
Januvia Sitagliptin Phosphate Brand 27 $41,833
Eliquis Apixaban Brand 32 $31,309
Farxiga Dapagliflozin Propanediol Brand 20 $31,265
Xarelto Rivaroxaban Brand 15 $23,321
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 14 $19,137
Atorvastatin Calcium Generic 569 $5,861
Humulin N Kwikpen Insulin Nph Human Isophane Brand 12 $5,500
Metoprolol Succinate Generic 273 $5,320
Lisinopril Generic 581 $4,556

The 10 drugs with the highest cost, of 92 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$81,953

Of which drugs: $495

Medicare patients

210

Average age 76

Services billed

1,182

88 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 25%
Chronic kidney disease 25%
Cancer 22%
Ischemic heart disease 20%
Depression 15%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 18 18 $394

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $108
$108 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $60
$60 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $48
$48 20 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $47
$47 — —
NURTEC ODT
  • PFIZER INC. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record